Patients with heart failure, irrespective of ejection fraction, frequently have AF. Disentangling whether a symptomatic patient presenting with AF has coexistent HFpEF can present a major clinical ...

While inconsistent dosing could have played a role, it still may be possible to identify the patients most likely to see ...

Inflammatory arthritis encompasses a group of autoimmune diseases, including rheumatoid arthritis (RA), psoriatic arthritis ...

In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have ...

Human Heat Tolerance Lower Than Previously Believed: Study FindsA study from the University of Ottawa’s Human and ...

Cardiac illnesses are among the trickier ones to manage in the limited time provided for many primary care visits, with ...

Tirzepatide offers a promising treatment for patients with obesity, chronic kidney disease, and heart failure, improving both ...

GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

A team of scientists led by Northwestern Medicine investigators have uncovered new details about a deadly heart condition ...

A gene therapy for heart failure with preserved ejection fraction (HFpEF), also known as diastolic heart failure, has shown ...

Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on targeting cardiovascular diseases by developing ...

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but ...